Homology Medicines, Inc.
Символ: 0T6G.L
LSE
21.56
USDПазарна цена днес
-0.7390
Съотношение P/E
-0.0083
Коефициент PEG
283.62M
MRK Cap
- 0.00%
Доходност на DIV
Homology Medicines, Inc. (0T6G-L) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 463.05 | 82.7 | 175 | 155.9 | ||||||||
balance-sheet.row.short-term-investments | 278.42 | 43.4 | 141 | 47.5 | ||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.other-current-assets | 12.42 | 1.3 | 6 | 36 | ||||||||
balance-sheet.row.total-current-assets | 475.47 | 83.9 | 181 | 191.9 | ||||||||
balance-sheet.row.property-plant-equipment-net | 62.06 | 0.7 | 21.6 | 17.9 | ||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.long-term-investments | 54.31 | 0 | 25.8 | 2 | ||||||||
balance-sheet.row.tax-assets | 221.56 | 221.6 | 0 | 0 | ||||||||
balance-sheet.row.other-non-current-assets | -115.73 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-non-current-assets | 337.93 | 222.2 | 47.5 | 19.8 | ||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-assets | 813.4 | 306.1 | 228.5 | 211.7 | ||||||||
balance-sheet.row.account-payables | 18.07 | 3.2 | 1.1 | 2.4 | ||||||||
balance-sheet.row.short-term-debt | 6.42 | 1.3 | 1.6 | 0.2 | ||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.long-term-debt-total | 49.42 | 49.4 | 11.9 | 5 | ||||||||
Deferred Revenue Non Current | -104.42 | -104.4 | 0 | 1.2 | ||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 221.56 | - | - | - | ||||||||
balance-sheet.row.other-current-liab | 53.47 | 7 | 18.7 | 11.4 | ||||||||
balance-sheet.row.total-non-current-liabilities | 302.61 | 221.6 | 27.9 | 24.8 | ||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.capital-lease-obligations | 87.84 | 6.8 | 27.9 | 23.7 | ||||||||
balance-sheet.row.total-liab | 380.92 | 233.1 | 50.5 | 42.1 | ||||||||
balance-sheet.row.preferred-stock | 111.44 | 111.4 | 111.4 | 111.4 | ||||||||
balance-sheet.row.common-stock | 0.02 | 0 | 0 | 0 | ||||||||
balance-sheet.row.retained-earnings | -2019.08 | -542.1 | -429.1 | -424.1 | ||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.31 | 0 | -0.4 | 0 | ||||||||
balance-sheet.row.other-total-stockholders-equity | 2340.4 | 503.6 | 496.1 | 482.3 | ||||||||
balance-sheet.row.total-stockholders-equity | 432.48 | 73 | 178 | 169.7 | ||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 813.4 | 306.1 | 228.5 | 211.7 | ||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-equity | 432.48 | 73 | 178 | 169.7 | ||||||||
balance-sheet.row.total-liabilities-and-total-equity | 813.4 | - | - | - | ||||||||
Total Investments | 332.73 | 43.4 | 166.9 | 49.4 | ||||||||
balance-sheet.row.total-debt | 87.48 | 1.3 | 29.5 | 23.9 | ||||||||
balance-sheet.row.net-debt | -97.15 | -37.9 | -4.5 | -84.4 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -112.96 | -113 | -5 | -95.8 | ||||||||
cash-flows.row.depreciation-and-amortization | 1.41 | 0.6 | 2.6 | 9.5 | ||||||||
cash-flows.row.deferred-income-tax | -7.31 | 0 | -19.2 | -38.8 | ||||||||
cash-flows.row.stock-based-compensation | 6.7 | 0 | 13.1 | 17.2 | ||||||||
cash-flows.row.change-in-working-capital | -7.21 | -7.2 | 3.4 | -41.8 | ||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.account-payables | 2.09 | 2.1 | -1 | -2.5 | ||||||||
cash-flows.row.other-working-capital | -9.3 | -9.3 | 4.3 | -39.3 | ||||||||
cash-flows.row.other-non-cash-items | 23.14 | 23.4 | -108.4 | 39.8 | ||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -96.23 | 0 | 0 | 0 | ||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 22.54 | -0.2 | -1.3 | -2.4 | ||||||||
cash-flows.row.acquisitions-net | -31.05 | 0.6 | 130 | 48.4 | ||||||||
cash-flows.row.purchases-of-investments | -73.24 | -73.2 | -157.5 | -97.4 | ||||||||
cash-flows.row.sales-maturities-of-investments | 174.24 | 174.2 | 65.5 | 49 | ||||||||
cash-flows.row.other-investing-activites | 69.84 | 0 | 0 | -48.4 | ||||||||
cash-flows.row.net-cash-used-for-investing-activites | 101.33 | 101.3 | 36.7 | -50.8 | ||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.common-stock-issued | 0.18 | 0.2 | 0.6 | 52.2 | ||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.other-financing-activites | 0.24 | 0 | 0.6 | 52.2 | ||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0.18 | 0.2 | 0.6 | 52.2 | ||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 21.11 | 0 | 0 | 0 | ||||||||
cash-flows.row.net-change-in-cash | 5.28 | 5.3 | -74.4 | -109 | ||||||||
cash-flows.row.cash-at-end-of-period | 184.63 | 39.3 | 34 | 108.4 | ||||||||
cash-flows.row.cash-at-beginning-of-period | 179.35 | 34 | 108.4 | 217.4 | ||||||||
cash-flows.row.operating-cash-flow | -96.23 | -96.2 | -113.7 | -109.8 | ||||||||
cash-flows.row.capital-expenditure | 22.54 | -0.2 | -1.3 | -2.4 | ||||||||
cash-flows.row.free-cash-flow | -73.69 | -96.5 | -114.9 | -112.1 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | -13.51 | 1.2 | 3.2 | 34 | ||||||||
income-statement-row.row.cost-of-revenue | 24.68 | 0.6 | 2.6 | 9.5 | ||||||||
income-statement-row.row.gross-profit | -38.18 | 0.6 | 0.6 | 24.4 | ||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.research-development | 62 | - | - | - | ||||||||
income-statement-row.row.selling-general-administrative | 26.16 | - | - | - | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 3.81 | - | - | - | ||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.operating-expenses | 91.97 | 92.7 | 133.9 | 120.4 | ||||||||
income-statement-row.row.cost-and-expenses | 93.26 | 93.3 | 136.5 | 129.9 | ||||||||
income-statement-row.row.interest-income | 5.58 | 5.6 | 3.2 | 0.2 | ||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 3.81 | - | - | - | ||||||||
income-statement-row.row.total-other-income-expensenet | 5.02 | 5 | 134.5 | 0.2 | ||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.total-operating-expenses | 5.02 | 5 | 134.5 | 0.2 | ||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.depreciation-and-amortization | 1.41 | 0.6 | 2.6 | 9.5 | ||||||||
income-statement-row.row.ebitda-caps | -90.81 | - | - | - | ||||||||
income-statement-row.row.operating-income | -92.1 | -92.1 | -133.3 | -95.9 | ||||||||
income-statement-row.row.income-before-tax | -87.08 | -87.1 | 1.2 | -95.8 | ||||||||
income-statement-row.row.income-tax-expense | 12.17 | 0.3 | 0.7 | 0.5 | ||||||||
income-statement-row.row.net-income | -112.96 | -113 | -5 | -95.8 |
Често задавани въпроси
Какво е Homology Medicines, Inc. (0T6G.L) общи активи?
Homology Medicines, Inc. (0T6G.L) общите активи са 306119000.000.
Какъв е годишният приход на предприятието?
Годишните приходи са -14662000.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -22.864.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -22.864.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 8.364.
Какъв е общият приход на предприятието?
Общият приход е 6.819.
Каква е Homology Medicines, Inc. (0T6G.L) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е -112961000.000.
Какъв е общият дълг на фирмата?
Общият дълг е 1318000.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 92680000.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 39266000.000.